~~<i id='8AE4304EF4'><strike id='8AE4304EF4'><tt id='8AE4304EF4'><pre id='8AE4304EF4'></pre></tt></strike></i>~~

Home» Wikipedia» leisure time

leisure time

author：leisure time 2025-10-02 05:23:00 Page View：71291

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What we owe ALS patients — and why one company fell short
Next article： After affirmative action ruling, medical educators look to 'holistic review'

focus

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Setback for rare diseases as Taysha Gene Therapies pulls back

AdobeIn2020,asbiotechstockssurgedamidthepandemic,astartupcalledTayshaGeneTherapiesraisedover$300mill

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Cell therapy fails to slow type 1 diabetes, but safety is established

AdobeToleranceistheholygrailincalmingautoimmunedisease,atruceintheimmunesystem’sfaultybattleagainstt